Skip to Content
Search Menu

Kohdunkaulasyövän seulonta tilastojen valossa

Syöpävaarallisia HPV-viruksia tunnistava testi on viime vuosina korvannut enenevässä määrin papakokeen kohdunkaulasyöpien seulontaohjelman ensisijaisena testinä. Haasteena on etenevien infektioiden ja esiasteiden erottaminen ohimenevistä.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Asiaan liittyvä sisältö

Continued Progress for the Treatment of Gynecological Cancer But No Game-Changer

/ BestPractice Nordic
ESMO24Gynecological cancer

The Choice of Immunotherapy and PARP Inhibitor for Gynecological Cancer

/ BestPractice Nordic
ESMO24Gynecological cancer
Mansoor Raza Mirza

ESMO 2024: Hope and Disappointment for Ovarian Cancer Treatment

/ Mansoor Raza Mirza
ESMO24Gynecological cancer Play the Video 09:55

ESMO24: New Standard of Care – Immunotherapy in High-Risk Locally Advanced Cervical Cancer

/ Jan Andreasen
ESMO24Gynecological cancer
Mansoor Raza Mirza

ESMO: Update on the ENGOT-EN6 RUBY Trial

/ Mansoor Raza Mirza
ESMO24Gynecological cancer Play the Video 02:46
Mansoor Raza Mirza

Mansoor Raza Mirza: ESMO is the Meeting Which Brings New Data for Forever Practice-Changing Trials

/ Mansoor Raza Mirza
ESMO24Gynecological cancer Play the Video 04:00

ASCO GU 2024: Updated Results from AVENANCE – Real-World Effectiveness of Avelumab in Patients with Advanced Urothelial Carcinoma

/ Sofie Pohl
ASCOGU24Gynecological cancer

The 2024 ASCO Genitourinary Cancers Symposium Will Be Covered by BestPractice Nordic

/ Sofie Pohl
ASCOGU24Gynecological cancer
Kristina Lindemann

ESMO 2023 Highlights: Practice-Changing Research in Gynecologic Cancers

/ Kristina Lindemann
ESMO23Gynecological cancerPatient involvement Play the Video 05:30
Back to top